ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. - Wikidata - awgldk - TriplyDB

ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.

ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.

http://www.wikidata.org/entity/Q34362322

about

Flaviviruses in Europe: complex circulation patterns and their consequences for the diagnosis and control of West Nile disease A Rapid and Improved Method to Generate Recombinant Dengue Virus Vaccine Candidates The yellow fever 17D virus as a platform for new live attenuated vaccines Vaccines in development against West Nile virus Experimental infection of rhesus macaques and common marmosets with a European strain of West Nile virus Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaques Vaccine-induced protection of rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virus Chimeric Dengue 2 PDK-53/West Nile NY99 Viruses Retain the Phenotypic Attenuation Markers of the Candidate PDK-53 Vaccine Virus and Protect Mice against Lethal Challenge with West Nile Virus A tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient mice A live, attenuated recombinant West Nile virus vaccine.Pathogenesis of West Nile Virus Infection: a Balance between Virulence, Innate and Adaptive Immunity, and Viral Evasion Monoclonal Antibody-Based Competitive Enzyme-Linked Immunosorbent Assay for Detecting and Quantifying West Nile Virus-Neutralizing Antibodies in Horse Sera Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses.The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells West Nile virus meningoencephalitis A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus.Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection.Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.RNA virus reverse genetics and vaccine design.Sequential immunization with heterologous chimeric flaviviruses induces broad-spectrum cross-reactive CD8+ T cell responses.A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination Current trends in West Nile virus vaccine development.The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys Flavivirus-induced antibody cross-reactivity.Yellow fever vaccine.Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment Repeated in vivo stimulation of T and B cell responses in old mice generates protective immunity against lethal West Nile virus encephalitis Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development.Use of viral vectors for the development of vaccines.Protective cancer immunotherapy: what can the innate immune system contribute?Single-dose vaccine against tick-borne encephalitis.

P2860

Q24273313-3C6ACC01-7615-4EC9-BCB5-7B2AEB5F1BB8 Q24282617-5C9F0CAF-1728-4D6C-A81F-D79E5BF352FD Q26865102-3CA4121E-E534-418E-983B-37BD93732E16 Q26999702-DDE62D4F-BA97-4EDB-8FEA-183D1088557B Q27304916-A4F11B0A-EAF4-48D1-9CF2-69F1AC1A2173 Q27319783-11FCFC84-505D-4366-BE09-BA691FD9D78F Q27329490-7B348FC4-BA7E-4D5E-85DC-E7F315F8041E Q27469831-B388D0D8-DFF1-4F38-8BAA-B6E9231DD74B Q27472824-D46A5279-83F3-4E40-80FB-7277B6EDEA33 Q27473138-52E2662C-14E2-4D3E-85D9-643D79B76CD0 Q27477543-C984F20D-2035-4636-BC16-0E0E8C9F24BF Q27478079-7825CCA3-9B2F-4965-91A1-600FC10633A1 Q27481420-DB67244B-0D9E-4E2F-84D1-EB1D547F6578 Q27486421-5D5686E3-FE77-43D4-B15F-19404119A90D Q27487448-FFB0E697-AE62-4106-89BD-0D315B6A3456 Q27487992-3099432F-697F-4D87-B6D5-13C3098DF2B9 Q28260103-FE90C218-219C-4F65-96C4-636C3CE65F06 Q28740740-82F99FB3-690D-4D2E-882D-A13F0568C59B Q30376550-007D3506-7AC8-4E89-A33B-FA76B7261584 Q30857727-8529E82E-AB33-421F-BDFD-92BFE3BC4789 Q33880730-AACF9964-0EBE-4C00-BE25-D068F0DAFB1C Q33909344-9AFC215E-EE02-463B-A829-83355AC3E608 Q33963398-161F7161-2C5B-461E-AC48-600983933F56 Q33992835-B8D075FD-C099-47EA-B556-8C3B8348441C Q34039347-E1508E0C-AA8E-476C-AE08-8067A7AC339B Q34109763-EC753C95-54D7-45C1-BA67-C143AEAF5C43 Q34154300-F7480870-94F6-4FD2-82A1-73C46B942531 Q34491896-43C06E24-AD9F-49B5-B13E-D365E3B8AF3B Q34764414-321D6A2E-4556-4F47-B202-A5BD91B406FD Q34788758-18FBF0C8-2700-4621-BF95-5CB254D61001 Q35492767-CDC0D3A0-CAE0-4DF2-82BA-5B8634BA9DF6 Q35961340-2C03BCE8-12F9-4CE9-808C-5B10E0D9BC10 Q36238729-FF6F3BAB-2D92-4C66-AC34-5CE60E85D8F6 Q36307457-D48C4FE5-831E-4271-9E39-8217D8F3371F Q36411126-D9393095-930F-4224-8961-6BD52BB311F5 Q36739363-76A04A96-453B-4C4B-A0EB-84E2E510A45D Q36780133-E3AD1B92-57EA-4982-AEE1-4C79E0B52A84 Q36780156-C54C2CC1-6D37-4428-B715-B81E6D18ED7E Q37032632-BDD34E96-DA3D-42A9-B39B-9EAEA5F88C1E Q37088625-67EA34C8-BFBE-4CAA-BB95-34601FC28E9C

P2860

ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.

http://www.wikidata.org/entity/Q34362322

description

2004 nî lūn-bûn

@nan

2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

ChimeriVax-West Nile virus liv ...... immunogenicity, and efficacy.

@ast

ChimeriVax-West Nile virus liv ...... immunogenicity, and efficacy.

@en

ChimeriVax-West Nile virus liv ...... immunogenicity, and efficacy.

@nl

type

label

ChimeriVax-West Nile virus liv ...... immunogenicity, and efficacy.

@ast

ChimeriVax-West Nile virus liv ...... immunogenicity, and efficacy.

@en

ChimeriVax-West Nile virus liv ...... immunogenicity, and efficacy.

@nl

prefLabel

ChimeriVax-West Nile virus liv ...... immunogenicity, and efficacy.

@ast

ChimeriVax-West Nile virus liv ...... immunogenicity, and efficacy.

@en

ChimeriVax-West Nile virus liv ...... immunogenicity, and efficacy.

@nl

P1433

Q34362322-AC1BF3CE-2C26-4C8D-A3F5-02E54D65A3FF

P1476

Q34362322-2A35EF84-65A8-4EEB-8882-437FC0343CD9

P2093

Q34362322-03A4C507-AAE7-4A2B-A8A8-51EC1817139D

Q34362322-09D6EC79-D9E5-4CC5-9F13-275BF0824F8D

Q34362322-2A18BE77-2AB6-403E-9417-B7EDCBE43D79

Q34362322-58323973-A1F5-4D3D-BF47-57B1DB2F333B

Q34362322-6F6E3347-0A49-4508-9255-EABB17676E49

Q34362322-FFE288BA-3235-4F8A-8102-30218FB52397

P2860

Q34362322-0B3670CF-F41B-4C97-9DD7-5D215E00639B

Q34362322-0BFCF2D4-CED9-42E8-9D65-5339650C9214

Q34362322-0D0D7382-E59D-4539-BC0C-207F75C92058

Q34362322-15B359D2-52E6-46FB-A1DB-0DF408D9FA84

Q34362322-1A2DCE80-56FA-4834-A79C-6F9F30695E1B

Q34362322-2AF012E7-1380-46AA-ABB9-642A61C668E0

Q34362322-2C698736-CC32-4478-BB2A-95CB7818EF5F

Q34362322-3AB3C779-C25F-46E2-B3D5-03CB1B38D34E

Q34362322-461A0256-7CB5-473F-A38C-5F8EFD9C9574

Q34362322-474B0FEE-DB5F-42EA-A112-286410856B13

P304

Q34362322-37963D31-732A-419B-B0B3-DFF6A7417828

P31

Q34362322-3EB3AA85-7CF8-45D6-9663-DCBC0C0C5D78

P356

Q34362322-69998C9B-F591-4B8D-A034-05B30FB54708

P407

Q34362322-C605D795-2D6A-4333-956F-35DB3145027E

P433

Q34362322-38A734E8-43E1-4F2E-913E-EC7B07915D82

P478

Q34362322-D27E1CD9-3416-4889-8DB0-0E90EE8ADC88

P50

Q34362322-AECE9337-6F04-4575-8A78-5C21D300752D

P577

Q34362322-3F69E2D9-06B5-4CC5-BF58-080503079CD3

P698

Q34362322-CBB83586-53C1-46CE-9805-7F41A45E088A

P921

Q34362322-BFD6C989-C646-4773-B63A-2D77F17B8FC9

Q34362322-D7CDE8C6-F910-433D-AFB7-72CD8980F31F

P932

Q34362322-9576C843-3856-4D48-9634-379358A155DE

P356

JVI.78.22.12497-12507.2004

P1433

Journal of Virology

P1476

ChimeriVax-West Nile virus liv ...... immunogenicity, and efficacy.

@en

P2093

Chuck Miller

http://www.w3.org/2001/XMLSchema#string

Dennis W Trent

http://www.w3.org/2001/XMLSchema#string

Gwendolyn A Myers

http://www.w3.org/2001/XMLSchema#string

John Catalan

http://www.w3.org/2001/XMLSchema#string

Juan Arroyo

http://www.w3.org/2001/XMLSchema#string

Marion S Ratterree

http://www.w3.org/2001/XMLSchema#string

P2860

Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties

Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.

Interaction of yellow fever virus French neurotropic vaccine strain with monkey brain: characterization of monkey brain membrane receptor escape variants

Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E

Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).

West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays.

Mutational Evidence for an Internal Fusion Peptide in Flavivirus Envelope Protein E

Neuroadapted yellow fever virus 17D: genetic and biological characterization of a highly mouse-neurovirulent virus and its infectious molecular clone

Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines.

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

P304

12497-12507

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.78.22.12497-12507.2004

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

78

http://www.w3.org/2001/XMLSchema#string

P50

Thomas P. Monath

P577

2004-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15507637

http://www.w3.org/2001/XMLSchema#string

P921

West Nile virus

attenuated vaccine

P932

525070

http://www.w3.org/2001/XMLSchema#string